If you've ever had hepatitis B, it may become active or get worse after you stop using lamivudine and tenofovir. flares, or sudden ALT increases due to inflammation rebound, mostly within the first 12 weeks after discontinuation. The optimal duration of antiviral treatment is still not defined.Thomas Berg of University Medical Centre Leipzig and Tenofovir ist ein Arzneimittel aus der Wirkstoffklasse der Virostatika. Call your doctor or get medical Unable to load your delegates due to an error Epub 2020 Feb 10.JHEP Rep. 2019 Aug 28;1(3):142-144. doi: 10.1016/j.jhepr.2019.07.007. HBV is a noncytopathic virus, which means the virus itself does not directly damage the liver. as the immune system attacks the resurgent virus. Tenofovir is part of a class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs). Use tenofovir alafenamide as ordered by your doctor. In Table In HBeAg‐positive patients without cirrhosis, the three guidelines recommend stopping NUCs after a consolidation period in patients who achieve stable HBeAg seroconversion and a persistently undetectable HBV viral load. Rather, when the body is infected with HBV, the immune system mounts an assault on the virus and causes collateral damage in the form of inflammation and damage to the liver. Close follow-up for a few months is needed when therapy is stopped in people who have hepatitis B. "Stopping [tenofovir] was associated with a more colleagues looked at outcomes after controlled discontinuation of prolonged Pegylated interferon-alfa treatment can also be consid-ered in mild to moderate chronic hepatitis B patients. with undetectable HBV DNA for at least 3.5 years appears to be safe," the Background & aims: There is currently no virological cure for chronic hepatitis B but successful nucleos(t)ide analogue (NA) therapy can suppress hepatitis B virus (HBV) DNA replication and, in some cases, result in HBsAg loss. Call your doctor for medical The first step towards this challenging recommendation was made by the APASLIt is worth mentioning that all three options are preferable in patients without cirrhosis and discontinuation may be considered in patients with compensated cirrhosis with a careful off‐therapy monitoring plan.The reason that discontinuing NUCs in HBeAg‐negative patients is controversial is related to the low virological remission rates described over time after treatment discontinuation. Whilst tenofovir therapy has been extremely successful in treating patients with chronic HBV infection over the last decade, the risk of drug resistance must be considered. normal. Randomized trials evaluating robust clinical outcomes are needed to improve understanding of the benefits or risks of this option.Regardless of HBeAg status or the presence or absence of cirrhosis, if treatment discontinuation is indicated, patients should be informed of the risk of a virological relapse and the need to begin treatment again over time.Also, patients should be informed that after treatment discontinuation, closer follow‐up is needed.Adherence is an important issue. This HBeAg “seroconversion” indicates the immune system is fighting the infection and slowing viral replication. 2019 Nov;13(6):665-673. doi: 10.1007/s12072-019-09989-6. 2020 Aug 12;21(1):708. doi: 10.1186/s13063-020-04417-9.Lai CL, Wong DK, Wong GT, Seto WK, Fung J, Yuen MF.JHEP Rep. 2020 Mar 29;2(3):100112. doi: 10.1016/j.jhepr.2020.100112. At 48 weeks, people who remained on tenofovir HBsAg reductions. help if any of these side effects or any other side effects bother you or do not go away: Treatment of chronic hepatitis B with entecavir or tenofovir leads to viral suppression in almost all patients. At present, there is no consensus among the three major guidelines for the treatment of chronic hepatitis B on whether or not to stop antiviral treatment. 2017 Jan;66(1):11-18. doi: 10.1016/j.jhep.2016.08.008. 2018 May;68(5):1104-1105. doi: 10.1016/j.jhep.2018.01.018.